Fidelity Investments’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-9,784
| Closed | -$128K | – | 5429 |
|
|
2025
Q4 | $128K | Sell |
9,784
-5,144,130
| -100% | -$61.4M | ﹤0.01% | 3626 |
|
|
2025
Q3 | $37.5M | Sell |
5,153,914
-1,304,887
| -20% | -$8.83M | ﹤0.01% | 1542 |
|
|
2025
Q2 | $34.6M | Sell |
6,458,801
-477,965
| -7% | -$2.32M | ﹤0.01% | 1520 |
|
|
2025
Q1 | $37M | Sell |
6,936,766
-886,963
| -11% | -$6.21M | ﹤0.01% | 1472 |
|
|
2024
Q4 | $69.9M | Buy |
7,823,729
+1,454
| +0% | +$15.4K | ﹤0.01% | 1260 |
|
|
2024
Q3 | $86.1M | Buy |
7,822,275
+1,767,714
| +29% | +$19.7M | 0.01% | 1162 |
|
|
2024
Q2 | $55.1M | Buy |
6,054,561
+1,735,404
| +40% | +$16.9M | ﹤0.01% | 1280 |
|
|
2024
Q1 | $60.8M | Sell |
4,319,157
-483,868
| -10% | -$6.03M | ﹤0.01% | 1254 |
|
|
2023
Q4 | $36.9M | Buy |
4,803,025
+2,237,973
| +87% | +$12.4M | ﹤0.01% | 1404 |
|
|
2023
Q3 | $19.1M | Sell |
2,565,052
-397,241
| -13% | -$3.39M | ﹤0.01% | 1598 |
|
|
2023
Q2 | $24.7M | Sell |
2,962,293
-255,685
| -8% | -$2.95M | ﹤0.01% | 1559 |
|
|
2023
Q1 | $42.8M | Sell |
3,217,978
-134,326
| -4% | -$1.82M | ﹤0.01% | 1318 |
|
|
2022
Q4 | $49.9M | Buy |
3,352,304
+2,974,859
| +788% | +$30.7M | 0.01% | 1255 |
|
|
2022
Q3 | $3.41M | Hold |
377,445
| – | – | ﹤0.01% | 2280 |
|
|
2022
Q2 | $1.13M | Buy |
377,445
+23,561
| +7% | +$106K | ﹤0.01% | 2648 |
|
|
2022
Q1 | $2.38M | Buy |
+353,884
| New | +$2.11M | ﹤0.01% | 2557 |
|
|
2020
Q4 | – | Sell |
-61,533
| Closed | -$2.29M | – | 3806 |
|
|
2020
Q3 | $2.29M | Buy |
+61,533
| New | +$2.44M | ﹤0.01% | 2281 |
|
|
2019
Q4 | – | Sell |
-32
| Closed | -$1K | – | 3766 |
|
|
2019
Q3 | $1K | Buy |
+32
| New | +$1.26K | ﹤0.01% | 3617 |
|
|
2017
Q1 | – | Sell |
-22,955
| Closed | -$4.97M | – | 2650 |
|
|
2016
Q4 | $4.97M | Sell |
22,955
-452
| -2% | -$111K | ﹤0.01% | 2179 |
|
|
2016
Q3 | $8.65M | Hold |
23,407
| – | – | ﹤0.01% | 2036 |
|
|
2016
Q2 | $5.2M | Sell |
23,407
-571
| -2% | -$172K | ﹤0.01% | 2167 |
|
|
2016
Q1 | $7.25M | Sell |
23,978
-310
| -1% | -$107K | ﹤0.01% | 2056 |
|
|
2015
Q4 | $11.6M | Sell |
24,288
-54
| -0.2% | -$25.9K | ﹤0.01% | 1932 |
|
|
2015
Q3 | $11.8M | Buy |
24,342
+80
| +0.3% | +$57.1K | ﹤0.01% | 1887 |
|
|
2015
Q2 | $17.8M | Buy |
+24,262
| New | +$18.3M | ﹤0.01% | 1774 |
|
Fidelity Investments's ATXS Position: Q1 2026 in Review
Fidelity Investments sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 9,784 shares — an estimated $128K sold.
Fidelity Investments first reported a position in ATXS in Q2 2015 and held it in 25 quarters. The position peaked at $86.1M in Q3 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Fidelity Investments reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Fidelity Investments sold 9,784 Astria Therapeutics shares in Q1 2026, an estimated $128K.
- Fidelity Investments first reported a position in Astria Therapeutics in Q2 2015 and held it in 25 quarters.
- Fidelity Investments's Astria Therapeutics position peaked at $86.1M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.